Induced stem cells

Global Cell Therapy Market Report 2021 Featuring Key Innovators Such as JCR Pharmaceuticals, NuVasive, Medipost, Vericel, and Avantor - Market to Reach $28.5 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021

Allogeneic cell therapy and non-Allogeneic cell therapy.\nAt present, there are two types of cell therapies exist.

Key Points: 
  • Allogeneic cell therapy and non-Allogeneic cell therapy.\nAt present, there are two types of cell therapies exist.
  • This category includes human embryonic stem cell therapy, mesenchymal stem cell therapy, neural stem cell therapy, Autologous cell therapy, and hematopoietic stem cell therapy.
  • The Stem Cell market dominated the Global Cell Therapy Market by Cell Type 2019, and is expected to continue to be a dominant market till 2026.
  • Based on the Analysis presented in the Cardinal matrix; Fujifilm Holdings Corporation is the major forerunner in the Cell Therapy Market.

Longeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific Affairs

Retrieved on: 
Tuesday, May 18, 2021

b'MIAMI, May 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the hiring of Dan Gincel, Ph.D. as Senior Vice President, Strategic Collaborations & Scientific Affairs.\nDr.

Key Points: 
  • b'MIAMI, May 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the hiring of Dan Gincel, Ph.D. as Senior Vice President, Strategic Collaborations & Scientific Affairs.\nDr.
  • Gincel brings over 20 years of leadership experience overseeing development and commercialization of regenerative medicines, including cell and gene therapies, as well as establishing public-private collaborations and corporate partnerships.
  • Additionally, he served as Executive Director at the Maryland Stem Cell Research Fund (MSCRF), where he managed over $150+ million in stem cell research funding.
  • During his tenure, he helped create and support more than 55 technology startup companies with over $120 million of follow-on funding and numerous successful exits.

Cytovia Therapeutics CEO Dr. Daniel Teper to Present at Two Upcoming Conferences

Retrieved on: 
Friday, May 14, 2021

Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer.

Key Points: 
  • Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer.
  • Cytovia\xe2\x80\x99s proprietary multi-specific antibody platform has been customized to engage and activate NK Cells at the tumor site.
  • Both platforms offer optionality to clinicians and can also be used synergistically.
  • Cytovia\xe2\x80\x99s R&D laboratories and GMP manufacturing facility are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, STC Biologics, and the University of California San Francisco (UCSF).\n'

Cytovia Therapeutics Expands Leadership Team

Retrieved on: 
Thursday, May 13, 2021

and AVENTURA, Fla., May 13, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic \xe2\x80\x9coff-the-shelf\xe2\x80\x9d gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Jason Aryeh, a long time biotech investor and board director, has been elected to the Cytovia Board of Directors, effective immediately.

Key Points: 
  • and AVENTURA, Fla., May 13, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic \xe2\x80\x9coff-the-shelf\xe2\x80\x9d gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Jason Aryeh, a long time biotech investor and board director, has been elected to the Cytovia Board of Directors, effective immediately.
  • \xe2\x80\x9cCytovia is uniquely positioned to become a leader in the rapidly growing field of NK (Natural Killer) Cancer Therapeutics.
  • Cytovia has the potential to positively affect the lives of many patients and consequently create substantial shareholder value in the next few years and beyond."\nMr.
  • Aryeh has more than twenty years of equity investment experience focused on the life sciences industry.

Citius Pharmaceuticals to Participate in Fireside Chat at the Gabelli Funds Virtual Microcap Symposium on Tuesday, May 18

Retrieved on: 
Tuesday, May 11, 2021

The Company\'s lead product candidate, Mino-Lok, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial.

Key Points: 
  • The Company\'s lead product candidate, Mino-Lok, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial.
  • Mino-Lok was granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
  • Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.
  • For more information, please visit www.citiuspharma.com .\nInvestor Relations for Citius Pharmaceuticals:\n'

Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and Regenerative Medicine Treatments

Retrieved on: 
Tuesday, May 11, 2021

b'Accelerated Biosciences, a regenerative medicine innovator, announced today new data that further demonstrates statistically significant cytolysis with induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells programmed from its ethically sourced human trophoblast stem cells (hTSCs).

Key Points: 
  • b'Accelerated Biosciences, a regenerative medicine innovator, announced today new data that further demonstrates statistically significant cytolysis with induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells programmed from its ethically sourced human trophoblast stem cells (hTSCs).
  • Pluristyx, a Seattle-based firm supporting drug development, regenerative medicine, and cell and gene therapies, further confirmed Accelerated Biosciences\xe2\x80\x99 hTSC line offers before-unrealized opportunities in cell-specific therapeutics.
  • We\xe2\x80\x99ve made IPS cells (induced pluripotent stem cells) and NK (natural killer) cells from them, which is the next wave of cells for cell therapies.
  • Accelerated Biosciences has discovered and is now offering what scientists see as the holy grail of stem cell sources.\xe2\x80\x9d\nProminent biosciences experts have been drawn to Accelerated Biosciences\xe2\x80\x99 cell breakthrough.

Factor Bioscience to Deliver Six Digital Presentations at the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting

Retrieved on: 
Tuesday, May 11, 2021

-to be presented by Mitchell Kopacz on May 11 from 8-10 am.\n"Removing T0 constraint reveals differences in specificity of engineered gene-editing proteins."

Key Points: 
  • -to be presented by Mitchell Kopacz on May 11 from 8-10 am.\n"Removing T0 constraint reveals differences in specificity of engineered gene-editing proteins."
  • -to be presented by Mackenzie Parmenter on May 11 from 8-10 am.\n"Knock-in iPS cell line generation using end-modified linear DNA donors."
  • For more information on the upcoming American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting, visit https://annualmeeting.asgct.org/\nFounded in 2011, Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease.
  • Factor collaborates with academic and industrial partners to develop therapeutic products based on its mRNA, gene editing, cell reprogramming, and nucleic-acid delivery technologies.

Therapeutic Solutions International Subsidiary Campbell Neurosciences Reports Positive Preclinical Data in Animal Model of Schizophrenia Using Proprietary Universal Donor Mesenchymal Stem Cell

Retrieved on: 
Monday, May 10, 2021

"Our data suggests similar effects may be induced by stem cell administration, which appears to possess a significantly superior safety profile than giving patients shocks with ultra-high voltage.

Key Points: 
  • "Our data suggests similar effects may be induced by stem cell administration, which appears to possess a significantly superior safety profile than giving patients shocks with ultra-high voltage.
  • "\nSchizophrenics appears to possess an immunological component given the abnormal inflammation and immune response skewing that occurs in these patients in the brain and the periphery.
  • This will allow us to file and clear multiple INDs," said Timothy Dixon, President and CEO of Therapeutic Solutions International and Founder of Campbell Neurosciences.
  • "We are encouraged and excited by the great support we have been having in providing the first stem cell based approach for mental illness.

Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells

Retrieved on: 
Thursday, May 6, 2021

Asymmetrex\'s first-in-kind kinetic stem cell (KSC) counting technology provides an effective solution to the decades old dilemma of there being no means to determine the stem cell dosage of stem cell treatments.\nSherley will be presenting the company\'s most recent improvements in its KSC counting technology.

Key Points: 
  • Asymmetrex\'s first-in-kind kinetic stem cell (KSC) counting technology provides an effective solution to the decades old dilemma of there being no means to determine the stem cell dosage of stem cell treatments.\nSherley will be presenting the company\'s most recent improvements in its KSC counting technology.
  • KSC counting can distinguish tissue stem cells, which are curative, from committed progenitor cells, which are not.
  • Finally knowing the stem cell dosage of stem cell treatments must necessarily be better for patients.
  • Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Aspen Neuroscience Announces Promotion of Andres Bratt-Leal, PhD, to Senior Vice President of Research & Development

Retrieved on: 
Wednesday, May 5, 2021

Bratt-Leal serves in Aspen\'s executive leadership, and leads the R&D team that developed the company\'s core technology platform: producing dopaminergic neurons from induced pluripotent stem cells (iPSCs).

Key Points: 
  • Bratt-Leal serves in Aspen\'s executive leadership, and leads the R&D team that developed the company\'s core technology platform: producing dopaminergic neurons from induced pluripotent stem cells (iPSCs).
  • Prior to co-founding Aspen, Andres also served as Senior Science Advisor and Director of Research and Development at Summit for Stem Cell Foundation, during which he led a team on the pre-clinical development of an autologous cell-based cell therapy for PD.
  • "\nHeadquartered in San Diego, Aspen Neuroscience, Inc. is a development stage, private biotechnology company focused on personalized (autologous) cell therapies.
  • For more information and important updates,please visit http://www.aspenneuroscience.com .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/aspen-neuroscience-announces-pro...\nSOURCE Aspen Neuroscience , Inc.\n'